These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 7202230)
21. Sinemet (CR4): an open-label study in moderately severe Parkinson's disease. Ming A; Temlett JA; Fritz VU J Intern Med; 1991 Aug; 230(2):113-7. PubMed ID: 1865161 [TBL] [Abstract][Full Text] [Related]
22. Parkinson's disease and motor fluctuations: long-acting carbidopa/levodopa (CR-4-Sinemet). Goetz CG; Tanner CM; Klawans HL; Shannon KM; Carroll VS Neurology; 1987 May; 37(5):875-8. PubMed ID: 3574696 [TBL] [Abstract][Full Text] [Related]
23. Randomized double-blind cross-over study of Sinemet-controlled release (CR4 50/200) versus Sinemet 25/100 in Parkinson's disease. Lieberman A; Gopinathan G; Miller E; Neophytides A; Baumann G; Chin L Eur Neurol; 1990; 30(2):75-8. PubMed ID: 2340838 [TBL] [Abstract][Full Text] [Related]
24. Sinemet in Parkinson's disease: efficacy with and without food. Bozek CB; Suchowersky O; Purves S; Calne S; Calne DB Clin Neuropharmacol; 1986; 9(2):196-9. PubMed ID: 3708604 [No Abstract] [Full Text] [Related]
26. Double-blind comparison of standard Sinemet and Sinemet CR in patients with mild-to-moderate Parkinson's disease. Feldman RG; Mosbach PA; Kelly MR; Thomas CA; Saint Hilaire MH Neurology; 1989 Nov; 39(11 Suppl 2):96-101; discussion 105. PubMed ID: 2685655 [TBL] [Abstract][Full Text] [Related]
27. Evaluation of equivalent efficacy of sinemet and sinemet CR in patients with Parkinson's disease applying levodopa dosage conversion formula. Manyam BV; Hare TA; Robbs R; Cubberley VB Clin Neuropharmacol; 1999; 22(1):33-9. PubMed ID: 10047932 [TBL] [Abstract][Full Text] [Related]
28. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. Block G; Liss C; Reines S; Irr J; Nibbelink D Eur Neurol; 1997; 37(1):23-7. PubMed ID: 9018028 [TBL] [Abstract][Full Text] [Related]
29. Controlled-release carbidopa-levodopa (Sinemet) in combination with standard Sinemet in advanced Parkinson's disease. Mark MH; Sage JI Ann Clin Lab Sci; 1989; 19(2):101-6. PubMed ID: 2665626 [TBL] [Abstract][Full Text] [Related]
30. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Hauser RA; Panisset M; Abbruzzese G; Mancione L; Dronamraju N; Kakarieka A; Mov Disord; 2009 Mar; 24(4):541-50. PubMed ID: 19058133 [TBL] [Abstract][Full Text] [Related]
31. A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance. Cedarbaum JM; Hoey M; McDowell FH J Neurol Neurosurg Psychiatry; 1989 Feb; 52(2):207-12. PubMed ID: 2649640 [TBL] [Abstract][Full Text] [Related]
32. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Olanow CW; Fahn S; Muenter M; Klawans H; Hurtig H; Stern M; Shoulson I; Kurlan R; Grimes JD; Jankovic J Mov Disord; 1994 Jan; 9(1):40-7. PubMed ID: 8139604 [TBL] [Abstract][Full Text] [Related]
33. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. Piccini P; Brooks DJ; Korpela K; Pavese N; Karlsson M; Gordin A J Neurol Neurosurg Psychiatry; 2000 May; 68(5):589-94. PubMed ID: 10766888 [TBL] [Abstract][Full Text] [Related]
34. Comparison of utilization of Sinemet and Parkinson's disease mortality as surrogate indicators of Parkinson's disease in the United States. Lanska DJ J Neurol Sci; 1997 Jan; 145(1):105-8. PubMed ID: 9073037 [TBL] [Abstract][Full Text] [Related]